Table 4.
Trajectory of IGF1 and IGF2 in T1DBIT subjects and analysis of AAb positivity
| Subject identification number | Age (years) | Sex | IGF1 | IGF2 | Number of AAb | GADA | IA-2A | IA-2βA | ZnT8A | IAA |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 14 | F | Stable | Stable | 1 | N | Y | N | N | N |
| 37 | 6 | F | Stable | Stable | 1 | N | N | N | N | Y→N |
| 13 | 10 | F | Stable | Stable | 1 | N | N | N | N | Y |
| 12 | 13 | F | Stable | Stable | 1 | N | N | N | N | Y |
| 25 | 14 | F | Stable | Stable | 1 | Y | N | N | N | N→Y |
| 19 | 14 | F | Stable | Stable | 1 | N | N | N | N | Y |
| 32 | 14 | M | Stable | Stable | 1 | N | N | N | N | Y |
| 34 | 16 | F | Stable | Stable | 1 | Y | N | N | N | N→Y→N |
| 27 | 16 | F | Stable | Stable | 1 | N | N | N | N | Y |
| 5 | 17 | F | Stable | Stable | 1 | N | N | N | N | Y→N |
| 29 | 18 | F | Stable | Stable | 1 | Y | N | N | N | N |
| 30 | 18 | F | Stable | Stable | 1 | N | N | N | N | Y |
| 22 | 33 | F | Stable | Up‡ | 1 | N | N | N | N | Y |
| 38 | 37 | F | Stable | Stable | 1 | N | N | N | N | Y |
| 36 | 12 | M | Stable | Stable | 2 | Y | N | N | N | Y |
| 26 | 18 | M | Stable | Stable | 2 | Y | N | N | N | Y |
| 3 | 8 | M | Stable | Stable | 2 | Y | N | N | Y→N | N |
| 33 | 6 | F | Stable | Stable | 2 | N | N | N→Y | Y→N | Y |
| 35 | 17 | F | Stable | Stable | 2 | Y | N | N | Y | N→Y→N→Y |
| 8 | 4 | M | Stable | Stable | 3 | Y | Y | Y | N | N→Y→N |
| 17 | 15 | F | Stable | Up‡ | 3 | Y | N | N | Y | Y→N |
| 31 | 13 | M | Stable | Stable | 4 | Y | Y | Y | Y | N |
| 2 | 15 | F | Stable | Stable | 4 | Y | Y | Y | Y | N |
| 4 | 18 | M | Stable | Up‡ | 4 | Y | Y | Y | Y | N |
| 11 | 35 | F | Stable | Stable | 4 | Y | Y | Y | Y | N |
| 18 | 17 | M | Stable | Stable | 4 | Y | Y | Y | Y | N→Y→N |
| 40 | 5 | M | Stable | Stable | 5 | Y | Y | Y | Y | Y |
| 23 | 14 | F | Down† | Up‡ | 3 | N→Y→N→Y | Y | Y | Y | N |
| 20 | 14 | M | Down† | Stable | 3 | N | Y | Y | Y | N→Y |
| 39 | 14 | F | Down† | Stable | 4 | Y | Y | Y | Y | N |
| 15 | 18 | F | Down† | Stable | 4 | Y | Y | Y | Y | N |
| 16 | 15 | M | Down† | Up‡ | 5 | Y | Y | Y | Y | Y |
| 10 | 17 | M | Down† | Stable | 5 | Y→N→Y | Y | Y | Y | Y |
| 9 | 11 | M | Up‡ | Stable | 3 | Y | N | N | Y | Y→N |
| 1* | 10 | M | Stable | Stable | 5 | Y | Y | Y | Y | Y |
| 28* | 17 | M | Stable | Stable | 4 | Y | Y | Y | Y | N→Y |
| 7* | 14 | M | Down† | Up‡ | 5 | Y | Y | Y | Y | Y→N→Y |
| 21* | 15 | M | Down† | Down† | 3 | N→Y | Y | Y | Y | N→Y |
| 14* | 17 | M | Down† | Down† | 4 | Y | Y | Y | Y | N→Y |
| 24* | 17 | F | Down† | Stable | 4 | Y | Y | Y | Y | N |
F, female; M, male; N, no; Y, yes. IGF trajectory designated as follows:
†levels significantly decreased or
‡significantly increased during the study, as determined by Spearman correlation of IGF level vs. time.
*These subjects developed type 1 diabetes during the study; therefore, IAA seroconversion may be a consequence of exogenous insulin therapy.